Tesamorelin

Tesamorelin API

ʻO Tesamorelin kahi lāʻau peptide synthetic, ʻo ka inoa piha ʻo ThGRF (1-44) NH₂, ʻo ia ka hormone hoʻokuʻu hormone ulu (GHRH) analog. Hoʻoulu ia i ka pituitary anterior e hūnā i ka hormone ulu (GH) ma ka hoʻohālikelike ʻana i ka hana o ka GHRH endogenous, a laila e hoʻonui i ke kiʻekiʻe o ka insulin-like growth factor 1 (IGF-1), e lawe mai ana i kahi ʻano o nā pono i ka metabolism a me ka hoʻoponopono kiko.

I kēia manawa, ua ʻae ʻia ʻo Tesamorelin e ka FDA no ka mālama ʻana i ka lipodystrophy pili i ka maʻi HIV, ʻoi loa no ka hōʻemi ʻana i ka momona visceral abdominal accumulation (visceral adipose tissue, VAT). Ua aʻo nui ʻia no ** anti-aging, metabolic syndrome, non-alcoholic fatty liver maʻi (NAFLD/NASH)** a me nā kula ʻē aʻe, e hōʻike ana i nā manaʻo noiʻi ākea.
Mechanism o ka hana

ʻO Tesamorelin kahi peptide 44-amino acid me kahi ʻano like loa me ka GHRH maoli. ʻO kāna ʻano hana:

E ho'ā i ka GHRH receptor (GHRHR) e hoʻoulu i ka pituitary anterior e hoʻokuʻu iā GH.

Ma hope o ka hoʻokiʻekiʻe ʻana o GH, hana ia ma ke ake a me nā ʻiʻo a puni e hoʻonui i ka synthesis IGF-1.

Hoʻopili pū ʻo GH a me IGF-1 i ka metabolism momona, synthesis protein, hoʻoponopono cell a me ka mālama ʻana i ka iwi.

Hoʻohana nui ia i ka decomposition momona visceral (momoli momona) a liʻiliʻi ka hopena i ka momona subcutaneous.

Ke hoʻohālikelike ʻia me ka hoʻokele exogenous pololei o GH, hoʻolaha ʻo Tesamorelin i ka huna ʻana o GH ma o nā hana endogenous, kahi kokoke loa i ka physiological rhythm a pale i nā hopena ʻino i hana ʻia e ka nui o ka GH, e like me ka paʻa ʻana o ka wai a me ke kūpaʻa insulin.

Ka noiʻi a me ka pono lapaʻau

Ua hōʻoia ʻia ka maikaʻi o Tesamorelin ma o nā hoʻokolohua lapaʻau he nui, ʻoi loa ma nā wahi aʻe:

1. Lipodystrophy pili i ka ma'i HIV (nā hō'ailona i'āpono 'ia e FDA)

Hiki i ka Tesamorelin ke hoʻemi nui i ka VAT o ka ʻōpū (ka emi ʻana o 15-20%);

Hoʻonui i nā pae IGF-1 a hoʻomaikaʻi i ke kūlana metabolic o ke kino;

Hoʻomaikaʻi i ke ʻano o ke kino a hoʻemi i ke kaumaha noʻonoʻo e pili ana i ka hāʻawi hou ʻana i ka momona;

ʻAʻole pili nui i ka papa momona subcutaneous, iwi iwi a i ʻole ka nui o ka ʻiʻo.

2. Non-alcoholic steatohepatitis (NASH) a me ka ate fibrosis

Ua hōʻike ʻia nā hoʻokolohua lapaʻau e hiki ai iā Tesamorelin ke hōʻemi i ka momona o ka ate (MRI-PDFF imaging);

Manaʻo ia e hoʻomaikaʻi i ka naʻau hepatocyte insulin;

He kūpono loa ia no nā poʻe maʻi me ka maʻi HIV a me ka NAFLD, a loaʻa iā ia ka pale metabolic ākea ākea.

3. Metabolic syndrome a me ka insulin resistance

Hoʻemi nui ʻo Tesamorelin i nā pae triglyceride a me ka momona o ka ʻōpū;

Hoʻomaikaʻi i ka helu HOMA-IR a kōkua i ka hoʻomaikaʻi ʻana i ka insulin resistance;

Ua hōʻike ʻia nā haʻawina e hiki ke hoʻonui i ka mana synthesis protein muscle, kahi mea e pono ai ka poʻe ʻelemakule a i ʻole ka hoʻihoʻi ʻana i ka maʻi maʻi.

ʻO ka hana API a me ka mana maikaʻi

ʻO ka Tesamorelin API i hāʻawi ʻia e kā mākou Gentolex Group e hoʻohana i ka ʻenehana peptide synthesis paʻa paʻa (SPPS) a hana ʻia ma lalo o ke kaiapuni GMP. Loaʻa iā ia nā ʻano penei:

Maʻemaʻe ≥99% (HPLC)
ʻAʻohe endotoxin, metala kaumaha, koena solvent detection qualified
ʻO ke kaʻina amino acid a me ka hōʻoia ʻana o ka hoʻolālā e LC-MS/NMR
Hāʻawi i ka pae gram-level a hiki i kilo-level hana maʻamau